BTK and obesity due to melanocortin 4 receptor deficiency: For example, Misselbeck et al. identified Bruton's tyrosine kinase (BTK) inhibitor ibrutinib as a prospective drug candidate for reducing chronic inflammatory conditions linked to obesity.[11] Jessica C et al. identified metformin as a repurposable drug for treating atrial fibrillation.[12] Fang et al. identified sildenafil as a candidate drug for Alzheimer's disease.[13] However, the usefulness of the network‐based approach has not yet been fully exploited for drug repositioning targeting ICP molecules in human cancer.